| Primary |
| Product Used For Unknown Indication |
26.0% |
| Cytomegalovirus Infection |
18.6% |
| Prophylaxis |
9.7% |
| Hiv Infection |
8.3% |
| Prophylaxis Against Transplant Rejection |
7.7% |
| Immunosuppression |
4.3% |
| Drug Use For Unknown Indication |
3.7% |
| Antiviral Prophylaxis |
2.9% |
| Cytomegalovirus Chorioretinitis |
2.9% |
| Hypertension |
2.9% |
| Small Intestine Transplant |
2.3% |
| Graft Versus Host Disease |
1.7% |
| Lung Transplant |
1.7% |
| Prophylactic Chemotherapy |
1.4% |
| Antiretroviral Therapy |
1.1% |
| Cytomegalovirus Viraemia |
1.1% |
| Depression |
1.1% |
| Anxiety |
0.9% |
| Asthma |
0.9% |
| Castleman's Disease |
0.9% |
|
| Death |
13.2% |
| Cytomegalovirus Infection |
8.8% |
| Agranulocytosis |
7.4% |
| Bone Marrow Failure |
7.4% |
| Pneumonia |
7.4% |
| Pancytopenia |
5.9% |
| Cytomegalovirus Chorioretinitis |
4.4% |
| Neutropenia |
4.4% |
| Platelet Count Decreased |
4.4% |
| Renal Impairment |
4.4% |
| Transplant Rejection |
4.4% |
| Vitreous Opacities |
4.4% |
| Chronic Hepatic Failure |
2.9% |
| Cytomegalovirus Viraemia |
2.9% |
| Delirium |
2.9% |
| Drug Resistance |
2.9% |
| Granulocytopenia |
2.9% |
| Haematotoxicity |
2.9% |
| Hepatitis |
2.9% |
| Interstitial Lung Disease |
2.9% |
|
| Secondary |
| Product Used For Unknown Indication |
21.5% |
| Prophylaxis Against Transplant Rejection |
13.8% |
| Prophylaxis |
10.8% |
| Hiv Infection |
9.4% |
| Renal Transplant |
8.0% |
| Cytomegalovirus Infection |
6.2% |
| Immunosuppression |
4.3% |
| Cytomegalovirus Chorioretinitis |
3.8% |
| Prophylaxis Against Renal Transplant Rejection |
3.1% |
| Hypertension |
2.5% |
| Antiviral Treatment |
2.2% |
| Mycobacterium Avium Complex Infection |
2.1% |
| Antiviral Prophylaxis |
1.9% |
| Small Intestine Transplant |
1.8% |
| Maternal Exposure During Pregnancy |
1.7% |
| Cytomegalovirus Viraemia |
1.5% |
| Drug Use For Unknown Indication |
1.5% |
| Liver Transplant |
1.3% |
| Lung Transplant |
1.3% |
| Transplant Rejection |
1.3% |
|
| Agranulocytosis |
9.4% |
| Thrombotic Microangiopathy |
8.5% |
| Bone Marrow Failure |
6.8% |
| Neutropenia |
6.8% |
| Cytomegalovirus Chorioretinitis |
6.0% |
| Drug Resistance |
6.0% |
| Pancytopenia |
6.0% |
| Thrombocytopenia |
6.0% |
| Transplant Rejection |
5.1% |
| Pyrexia |
4.3% |
| Retinal Disorder |
4.3% |
| Cytolytic Hepatitis |
3.4% |
| Encephalopathy |
3.4% |
| Platelet Count Decreased |
3.4% |
| Renal Failure Acute |
3.4% |
| Sepsis |
3.4% |
| Spinal Compression Fracture |
3.4% |
| Vomiting |
3.4% |
| Weight Decreased |
3.4% |
| White Blood Cell Count Decreased |
3.4% |
|
| Concomitant |
| Product Used For Unknown Indication |
28.5% |
| Prophylaxis |
12.1% |
| Renal Transplant |
11.9% |
| Immunosuppression |
7.3% |
| Prophylaxis Against Transplant Rejection |
5.5% |
| Multiple Myeloma |
4.2% |
| Hiv Infection |
3.5% |
| Antiviral Prophylaxis |
3.0% |
| Immunosuppressant Drug Therapy |
3.0% |
| Drug Use For Unknown Indication |
2.6% |
| Infection Prophylaxis |
2.5% |
| Hypertension |
2.3% |
| Diffuse Large B-cell Lymphoma |
2.0% |
| Cytomegalovirus Infection |
1.8% |
| Heart Transplant |
1.8% |
| Pain |
1.8% |
| Antifungal Prophylaxis |
1.7% |
| Tuberculosis |
1.7% |
| Constipation |
1.5% |
| Prophylaxis Against Renal Transplant Rejection |
1.4% |
|
| Transplant Rejection |
9.1% |
| Vomiting |
9.1% |
| Cytomegalovirus Infection |
7.3% |
| Renal Impairment |
7.3% |
| Febrile Neutropenia |
6.7% |
| Death |
5.5% |
| Pyrexia |
5.5% |
| White Blood Cell Count Decreased |
5.5% |
| Immune Reconstitution Syndrome |
4.8% |
| Urinary Tract Infection |
4.8% |
| Sepsis |
4.2% |
| Thrombocytopenia |
4.2% |
| Anaemia |
3.6% |
| Atrial Fibrillation |
3.6% |
| Pain |
3.6% |
| Bone Marrow Oedema |
3.0% |
| Diarrhoea |
3.0% |
| Drug Ineffective |
3.0% |
| Leukopenia |
3.0% |
| Nausea |
3.0% |
|
| Interacting |
| Heart Transplant |
50.0% |
| Bk Virus Infection |
16.7% |
| Cytomegalovirus Infection |
16.7% |
| Multiple Myeloma |
16.7% |
|
| Discomfort |
33.3% |
| Neutropenia |
33.3% |
| Platelet Count Decreased |
33.3% |
|
